INIPARIB + irinotecan
Phase 2CompletedDevelopment Stage
Estrogen Receptor Negative (ER-Negative) Breast Cancer
Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer, Brain Metastases
Jul 1, 2010 → Jul 1, 2013
About INIPARIB + irinotecan
INIPARIB + irinotecan is a phase 2 stage product being developed by Sanofi for Estrogen Receptor Negative (ER-Negative) Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01173497. Target conditions include Estrogen Receptor Negative (ER-Negative) Breast Cancer, Progesterone Receptor Negative (PR-Negative) Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer.
What happened to similar drugs?
1 of 3 similar drugs in Estrogen Receptor Negative (ER-Negative) Breast Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01173497 | Phase 2 | Completed |
Competing Products
20 competing products in Estrogen Receptor Negative (ER-Negative) Breast Cancer